Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Sallie Astor Burdine Breast Foundation currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter represents the current focus of the foundation's patent prosecution efforts. The portfolio's examination is conducted by 1 distinct examiner and is located within 1 distinct art unit.
The examiner assigned to this matter is BENZION, GARY, who is identified as the busiest examiner with 1 pending office action. Because the 1 pending office action is the only one listed, BENZION, GARY is responsible for the whole of the active portfolio. This concentration means the prosecution outcome is directly tied to the interactions with this specific individual within the 1 distinct art unit.
For the practitioner, this structure requires a strategy focused on the specific tendencies and requirements of BENZION, GARY. There are no other examiners or art units mentioned in the data to provide alternative paths for patent procurement. The practitioner must ensure that the technical arguments are precisely aligned with the standards of the 1 distinct art unit involved to secure the foundation's intellectual property.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENZION, GARY | 1 | 21.1% | +13.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791785 | COMPOSITIONS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE DISEASES | BENZION, GARY | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791785 | COMPOSITIONS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE DISEASES | BENZION, GARY | 15d |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17791785 | COMPOSITIONS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE DISEASES | BENZION, GARY | 1681 | §103§112 | Non-Final OA | 15d | Pending | Jul 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial